HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies ...
Following the acquisition, Bio-Rad introduced its first product with this technology, QX100 Droplet Digital PCR system, the third generation of the polymerase chain reaction (:PCR) technology. This ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and NuProbe USA, a genomics and molecular diagnostics company, recently ...
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...
Hercules, CA -- October 19, 2015 -- Bio-Rad's Droplet Digital PCR (ddPCR™) technology identifies viral RNA mutations in clinical samples with greater precision, sensitivity, and reproducibility than ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...
ddPCR reportedly provides quantification of target molecules with unprecedented precision and sensitivity. Bio-Rad Laboratories purchased QuantaLife for $162 million in cash plus future milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results